Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3

详细信息    查看全文

• 作者：Eun-ju Do ; Sung Wook Hwang ; Sang-Yeob Kim ; Yeon-Mi Ryu ; Eun A. Cho ; Eun-Ju Chung ; Sunha Park ; Hyo Jeong Lee ; Jeong-Sik Byeon ; Byong Duk Ye ; Dong-Hoon Yang ; Sang Hyoung Park ; Suk-Kyun Yang ; Jin-Ho Kim and Seung-Jae Myung
• 刊名：Journal of Gastroenterology and Hepatology
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：31
• 期：8
• 页码：1453-1461
• 全文大小：418K
• ISSN：1440-1746

文摘

Recent studies suggest that the anti-inflammatory agent balsalazide (BSZ) and probiotic agent VSL#3 have potential therapeutic benefits for the treatment of patients with inflammatory bowel disease. However, their effectiveness in preventing colitis-associated carcinogenesis (CAC) remains uncertain. The aim of the present study was to determine the chemopreventive effects of BSZ and VSL#3 in the murine azoxymethane (AOM)/dextran sodium sulfate (DSS) model.